Meeting
2023 ASCO Annual Meeting
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
Authors
Joseph Christopher Murray
Johns Hopkins Kimmel Cancer Center, Baltimore, MD
Joseph Christopher Murray , Debra AG McIntyre , Valsamo Anagnostou , Julie R. Brahmer , Alexander Meisel , Ahmet Sezer , Miranda Gogishvili , Tamar Melkadze , Ana Baramidze , Tamta Makharadze , Adam He , Siyu Li , Vladimir Jankovic , Frank A. Seebach , Petra Rietschel , Young J. Kim , Giuseppe Gullo , Jean-Francois Pouliot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT03088540 and NCT03409614
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9028)
DOI
10.1200/JCO.2023.41.16_suppl.9028
Abstract #
9028
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
First Author: Mahmut Gumus
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
First Author: Jeddeo Paul
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse